For your patients with ADHD who are 6 years and older
QuilliChew ER® delivers
Their days may not be consistent but their medication should be.
Unique technology provides continuous release of methylphenidate1
• Lasting improvements in attention and behavior2
Effective symptom control
through the most important
parts of the day2
Smooth
PK profile3,4
Most dosing options in an
ER methylphenidate tablet
Request more information about QuilliChew ER
Click below to sign up to receive more information about QuilliChew ER.
You can also request a visit from a Tris Pharma representative.
ADHD, Attention Deficit Hyperactivity Disorder; ER, extended-release; IR, immediate-release; PK, pharmacokinetic.
References: 1. Kando JC, King TR, Pardo A. A novel, modified-release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at: American Psychiatric Association Annual Meeting; May 1-3, 2021. 2. Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(8):690-699. 3. QuilliChew ER [package insert]. Tris Pharma, Inc., Monmouth Junction 4. Abbas R, Palumbo D, Walters F, et al. Single-dose pharmacokinetic properties and relative bioavailability of a novel methylphenidate extended-release chewable tablet compared with immediate-release methylphenidate chewable tablet; 2016. Clin Ther. 2016;28(5): 1151-1157.